scholarly journals Costs Associated with Health Care Resource Use in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Treatment with Pazopanib Versus Sunitinib

2014 ◽  
Vol 17 (3) ◽  
pp. A77-A78
Author(s):  
M.D. Hackshaw ◽  
R.N. Hansen ◽  
S.P. Nagar ◽  
B. Arondekar ◽  
K.C. Deen ◽  
...  
Keyword(s):  
Health Care ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Resource Use ◽  
Renal Cell ◽  
Health Care Resource ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma

2020 ◽  
Vol 36 (9) ◽  
pp. 1507-1517
Author(s):  
Arielle G. Bensimon ◽  
Yichen Zhong ◽  
Umang Swami ◽  
Allison Briggs ◽  
Joshua Young ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma

2010 ◽  
Vol 13 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Martin Hoyle ◽  
Colin Green ◽  
Jo Thompson-Coon ◽  
Zulian Liu ◽  
Karen Welch ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document